Mdma molecule:

Image from PubChem

Mdma Clinical Trials


Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05523401

Organisation Name: University Hospital, Basel, Switzerland

Overal Status: Not yet recruiting

Start Date: December 31, 2022

Last Update: August 31, 2022

Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary: 2-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic, hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its reported mixed effects profile. However, scientific studies are lacking. There is an increased interest in psychiatric research on the therapeutic properties of MDMA and psilocybin and also on mixed empathogenic-psychedelic substances.

Conditions:
  • Healthy


Total execution time in seconds: 0.30522704124451